Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Blood-based NfL : A biomarker for differential diagnosis of parkinsonian disorder. / Hansson, Oskar; Janelidze, Shorena; Hall, Sara; Magdalinou, Nadia; Lees, Andrew J; Andreasson, Ulf; Norgren, Niklas; Linder, Jan; Forsgren, Lars; Constantinescu, Radu; Zetterberg, Henrik; Blennow, Kaj; Swedish BioFINDER study group.

I: Neurology, Vol. 88, Nr. 10, 07.03.2017, s. 930-937.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Hansson, O, Janelidze, S, Hall, S, Magdalinou, N, Lees, AJ, Andreasson, U, Norgren, N, Linder, J, Forsgren, L, Constantinescu, R, Zetterberg, H, Blennow, K & Swedish BioFINDER study group 2017, 'Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder', Neurology, vol. 88, nr. 10, s. 930-937. https://doi.org/10.1212/WNL.0000000000003680

APA

CBE

Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K, Swedish BioFINDER study group. 2017. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology. 88(10):930-937. https://doi.org/10.1212/WNL.0000000000003680

MLA

Vancouver

Author

Hansson, Oskar ; Janelidze, Shorena ; Hall, Sara ; Magdalinou, Nadia ; Lees, Andrew J ; Andreasson, Ulf ; Norgren, Niklas ; Linder, Jan ; Forsgren, Lars ; Constantinescu, Radu ; Zetterberg, Henrik ; Blennow, Kaj ; Swedish BioFINDER study group. / Blood-based NfL : A biomarker for differential diagnosis of parkinsonian disorder. I: Neurology. 2017 ; Vol. 88, Nr. 10. s. 930-937.

RIS

TY - JOUR

T1 - Blood-based NfL

T2 - A biomarker for differential diagnosis of parkinsonian disorder

AU - Hansson, Oskar

AU - Janelidze, Shorena

AU - Hall, Sara

AU - Magdalinou, Nadia

AU - Lees, Andrew J

AU - Andreasson, Ulf

AU - Norgren, Niklas

AU - Linder, Jan

AU - Forsgren, Lars

AU - Constantinescu, Radu

AU - Zetterberg, Henrik

AU - Blennow, Kaj

AU - Swedish BioFINDER study group

AU - Lätt, Jimmy

PY - 2017/3/7

Y1 - 2017/3/7

N2 - Objective: To determine if blood neurofilament light chain (NfL) protein can discriminate between Parkinson disease (PD) and atypical parkinsonian disorders (APD) with equally high diagnostic accuracy as CSF NfL, and can therefore improve the diagnostic workup of parkinsonian disorders. Methods: The study included 3 independent prospective cohorts: the Lund (n = 278) and London (n = 117) cohorts, comprising healthy controls and patients with PD, progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA), as well as an early disease cohort (n = 109) of patients with PD, PSP, MSA, or CBS with disease duration ≤3 years. Blood NfL concentration was measured using an ultrasensitive single molecule array (Simoa) method, and the diagnostic accuracy to distinguish PD from APD was investigated. Results: We found strong correlations between blood and CSF concentrations of NfL (ρ ≥ 0.73-0.84, p ≤ 0.001). Blood NfL was increased in patients with MSA, PSP, and CBS (i.e., all APD groups) when compared to patients with PD as well as healthy controls in all cohorts (p < 0.001). Furthermore, in the Lund cohort, blood NfL could accurately distinguish PD from APD (area under the curve [AUC] 0.91) with similar results in both the London cohort (AUC 0.85) and the early disease cohort (AUC 0.81). Conclusions: Quantification of blood NfL concentration can be used to distinguish PD from APD. Blood-based NfL might consequently be included in the diagnostic workup of patients with parkinsonian symptoms in both primary care and specialized clinics. Classification of evidence: This study provides Class III evidence that blood NfL levels discriminate between PD and APD.

AB - Objective: To determine if blood neurofilament light chain (NfL) protein can discriminate between Parkinson disease (PD) and atypical parkinsonian disorders (APD) with equally high diagnostic accuracy as CSF NfL, and can therefore improve the diagnostic workup of parkinsonian disorders. Methods: The study included 3 independent prospective cohorts: the Lund (n = 278) and London (n = 117) cohorts, comprising healthy controls and patients with PD, progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA), as well as an early disease cohort (n = 109) of patients with PD, PSP, MSA, or CBS with disease duration ≤3 years. Blood NfL concentration was measured using an ultrasensitive single molecule array (Simoa) method, and the diagnostic accuracy to distinguish PD from APD was investigated. Results: We found strong correlations between blood and CSF concentrations of NfL (ρ ≥ 0.73-0.84, p ≤ 0.001). Blood NfL was increased in patients with MSA, PSP, and CBS (i.e., all APD groups) when compared to patients with PD as well as healthy controls in all cohorts (p < 0.001). Furthermore, in the Lund cohort, blood NfL could accurately distinguish PD from APD (area under the curve [AUC] 0.91) with similar results in both the London cohort (AUC 0.85) and the early disease cohort (AUC 0.81). Conclusions: Quantification of blood NfL concentration can be used to distinguish PD from APD. Blood-based NfL might consequently be included in the diagnostic workup of patients with parkinsonian symptoms in both primary care and specialized clinics. Classification of evidence: This study provides Class III evidence that blood NfL levels discriminate between PD and APD.

UR - http://www.scopus.com/inward/record.url?scp=85014848691&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000003680

DO - 10.1212/WNL.0000000000003680

M3 - Article

VL - 88

SP - 930

EP - 937

JO - Neurology

JF - Neurology

SN - 1526-632X

IS - 10

ER -